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Abstract Sorafenib and sunitinib are used for renal cell
carcinoma (RCC). The objective was to study the treatment
duration and time to death in Swedish RCC patients on
sorafenib or sunitinib as first-line or monotherapy or as
sequential therapy. Patients with an RCC diagnosis were
identified in the Swedish Cancer Register. Information on
treatment with sorafenib and sunitinib was collected from
the Swedish Prescribed Drug Register, and time of death
from the Cause of Death Register. Outcome measures were
duration of treatment and time to death on sorafenib or
sunitinib as first-line or monotherapy and sequential ther-
apy (sorafenib–sunitinib versus sunitinib–sorafenib). Pois-
son regression models were used to estimate hazard ratios
(HR) with 95 % confidence intervals (CI). No difference
was observed for sorafenib (n = 123 patients) versus
sunitinib (n = 261 patients) in treatment duration (HR
1.00; CI 0.80–1.24) or risk for death (HR 1.30; CI
0.91–1.85) when used as first-line or monotherapy. The
same applied for sequential therapy with sorafenib–suniti-
nib (n = 43 patients) versus sunitinib–sorafenib (n = 54
patients), HR 1.47 (CI 0.71–3.02) and HR 2.01 (CI
0.86–4.68), respectively. There was a difference between
the two treatments in how the duration of first-line treat-
ment influenced the duration of second-line treatment and
time to death, in favor of starting with sorafenib. In con-
clusion, no difference was detected between sorafenib and
sunitinib in the duration of treatment or time to death when
used as first-line or monotherapy. The impact of the
duration of first-line treatment differed between the two
sequences, and the results indicated that sorafenib as first-
line treatment is a favorable choice.
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Introduction
Renal cell carcinoma (RCC) accounts for nearly 2 % of all
malignancies in the adult Swedish population [1]. Close to
a thousand new cases are diagnosed every year in Sweden.
For metastatic RCC, the median survival was estimated to
6–12 months in 2003 [2]. RCC is resistant to conventional
therapies such as chemotherapy, radiotherapy, and hor-
monal therapy. The only two treatment alternatives avail-
able for inoperable or metastatic disease until a few years
ago were interferon alpha (IFN-a) and interleukin 2 (IL-2)
therapy. Only a small proportion of patients was eligible
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for and responded well to these treatments. Improved
understanding of the molecular mechanisms associated
with the disease, including increased transcription of vas-
cular endothelial growth factor (VEGF), platelet-derived
growth factor, and epidermal growth factor, has led to the
development of multiple agents targeting RCC-promoting
pathways. Sorafenib and sunitinib are two multiple tyrosine
kinase inhibitors (TKIs) that, among other actions, block
the intracellular domain of the VEGF receptor. Inhibition
of the VEGF pathway decreases vascularization and
endothelial cell proliferation and obstructs tumor growth.
The two drugs were approved by the US Food and Drug
Administration (FDA) in 2005/2006 and the European
Medicines Agency in 2006 and have ameliorated the
prognosis of advanced RCC [3–6].
Although the new therapeutic opportunities have
improved the treatment of patients with RCC, patients will
eventually develop tumor progression due to drug resis-
tance or toxicity leading to dose reduction and inadequate
drug levels. Clinical experience has shown that when
resistant to one of the TKI agents, patients can often benefit
by switching to the other, resulting in sequential use of the
two drugs, sorafenib and sunitinib, respectively. These
experiences suggest that only limited cross-resistance
exists between the two agents [7, 8]. While several new
treatment options for RCC have recently become available,
such as other TKIs and mammalian target of rapamycin
(mTOR) inhibitors, the optimal sequence for these various
drugs has not yet been established [9, 10].
The majority of the previous studies on sequential
therapy comparing sorafenib followed by sunitinib to
sunitinib followed by sorafenib found that the sequence by
which the agents are administered affected patient out-
comes, where sorafenib followed by sunitinib appeared to
be the most favorable sequence [7, 11–17]. In one of these
studies, the probability of proceeding to second-line treat-
ment was higher among patients starting with sorafenib
compared to those starting with sunitinib [13]. This could
indicate differences in effectiveness, tolerability and/or
survival rates while on first-line treatment with sorafenib
versus sunitinib. However, the analyses in all of these
previous studies have included only patients who were
treated with sequential therapy. This creates an artificial
survival advantage, since only patients surviving long
enough to start with second-line treatment are included.
Survivorship bias or immortal time bias is thus introduced.
Immortal time refers to the time during which the outcome
could not occur [18], and this should be accounted for in
the analyses.
The objective of this study was to study the treatment
duration and time to death in Swedish RCC patients on
sorafenib or sunitinib as first-line or monotherapy or as
sequential therapy.
Materials and methods
Data sources
This was a nationwide, observational study based on three
registers covering the entire Swedish population: the
Swedish Cancer Register (SCR) with information on the
primary tumor and its location, cell type, and stage at the
time of diagnosis for all types of cancer patients; the
Swedish Prescribed Drug Register (SPDR) with informa-
tion on dispensed drugs from Swedish pharmacies (i.e., not
drugs provided within hospitals); and the Cause of Death
Register (CDR) including information on time and cause of
death. The National Board of Health and Welfare main-
tains all three registers and performed the register linkages
using the unique personal identification number. The study
was approved by the Regional Ethical Review Board in
Gothenburg.
Patient population
Patients with a diagnosis of RCC from January 1, 1980, to
December 31, 2008, were first identified in the SCR. The
information collected from the SCR included T-, N- and
M-stages and morphological diagnosis along with date of
diagnosis. The data were linked to the SPDR, and RCC
patients undergoing treatment with sorafenib and/or suni-
tinib from 1 July, 2005, to 31 December, 2009, were
included if the date of the RCC diagnosis preceded the date
of the first purchase of sorafenib or sunitinib. Demographic
data at the time of diagnosis were collected from the SCR.
Time of death was collected from the CDR, where data
were available until 8 March, 2010.
Patients treated with IFN-a (alone or in combination
with bevacizumab) prior to initiation of sorafenib or suni-
tinib or between the two treatment regimens were exclu-
ded, that is, patients included in the study were naı¨ve to
oncologic drugs before starting with TKIs.
Outcome measures
The outcome measures were duration of treatment and time to
death on sorafenib or sunitinib as first-line or monotherapy
and on sequential therapy (sorafenib–sunitinib versus suniti-
nib–sorafenib). Patients were assumed to be on treatment from
the date of the first purchase and as long as purchases were
made. The stop date was defined as the date of the last pur-
chase plus the number of days the purchased amount would
last if the recommended dose according to the Swedish phy-
sician’s desk reference [19] was used. For sorafenib, this dose
was 400 mg twice daily. The dose for sunitinib was 50 mg
daily for 4 weeks followed by 2 weeks off treatment, also
included in the time of treatment duration.
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Statistical analyses
This study included analyses of duration of treatment and
time to death among RCC patients on sorafenib or sunitinib
as first-line or monotherapy and as sequential therapy. To
compare the treatment groups with regard to demographics
and baseline characteristics, Mann–Whitney U test was
used for continuous variables, Fisher’s exact test for
dichotomous variables, and Mantel–Haenszel chi-square
test for ordered categorical variables. Estimated median
and interquartile range (IQR) of the time to event was
obtained from unadjusted Kaplan–Meier curves, and
p values were calculated with log-rank tests. Poisson
regression models were used to estimate hazard functions
and determine hazard ratios (HR) with 95 % confidence
intervals (95 % CI) and p values. All significance tests
were two-sided at the significance level 0.05. The statistical
analyses were performed using SAS version 9.2.
Analyses of first-line or monotherapy
The outcome variable treatment duration was defined as the
time from treatment start to treatment stop, death or switch
to the other TKI or to IFN-a (most likely in combination
with bevacizumab). Patients were censored at 31 Decem-
ber, 2009 (last date with information from the SPDR), if
treatment was still ongoing. For the outcome variable time
to death while the patient was still on treatment, censoring
occurred at treatment stop, switch to the other TKI or to
IFN-a (most likely in combination with bevacizumab), or
on the last date with information from the SPDR (31
December, 2009).
The adjusted Poisson regression models included all
baseline variables both statistically associated with the
exposure category (sorafenib versus sunitinib) and with the
outcome variables treatment duration and time to death,
respectively. The rationale for considering calendar year
for treatment start as a potential confounder was that the
use of sorafenib and sunitinib was unevenly distributed
over time, where sorafenib was more commonly used in the
beginning and sunitinib was more commonly used in the
end of the study period.
Analyses of sequential treatment
In an initial analysis of duration of treatment and time to
death on sequential treatment, only patients treated with
sorafenib followed by sunitinib and with sunitinib followed
by sorafenib were included, and the same statistical anal-
yses as now applied for first-line or monotherapy were
used. To avoid immortal time bias in subsequent analyses,
patients surviving first-line therapy were assumed to be
subjected to second-line treatment, thereby accounting for
the risk of death or treatment stop among patients treated
with monotherapy, that is, sorafenib or sunitinib only. Four
hazard functions (h1–h4) were developed with Poisson
regression models; h1–h2 concerns first-line treatment, and
h3–h4 concerns second-line treatment. All patients initiated
on sorafenib or sunitinib were included in the estimation of
h1–h2, independently of whether or not they were subject
to second-line treatment thereafter. The functions h3–h4
included only patients for whom sequential treatment
(sorafenib–sunitinib and sunitinib–sorafenib) was observed.
An overview of the hazard functions is given in Table 1.
Please, see the online Supplementary Material for a more
detailed description. In h1 and h2, the follow-up started
from the initiation of first-line or monotherapy and ended at
death or stop of first-line treatment (h1) or treatment stop
only (h2). In h3 and h4, the follow-up started at the initi-
ation of second-line treatment and ended at the stop of
second-line treatment (h3) or death (h4). A direct switch to
second-line therapy after discontinuation of first-line ther-
apy was assumed, that is, the time between the two treat-
ments was not included. Time on first-line treatment was
included as a covariate in h3–h4, and calendar year for
treatment start was included as a covariate in all functions.
The method briefly presented above and in more detail
in the Supplementary Material has also been used for the
statistical application in FRAX [20], also developed by one
of the co-authors, professor Anders Ode´n. The FRAX tool
was created by the World Health Organization (WHO), and
the algorithm calculates fracture probability based on
Poisson regression models from which hazard functions are
estimated.
Results
First-line or monotherapy
First-line or monotherapy with sorafenib was observed
among 123 patients and with sunitinib among 261 patients.
No differences in demographics or baseline characteristics
were observed between the two groups, except for calendar
year for treatment start (Table 2). In the unadjusted Poisson
regression analysis, calendar year for treatment start was a
statistically significant predictor for time to death (HR
0.77; 95 % CI 0.63–0.95; p = 0.0132), but not for treat-
ment duration (HR 1.06; 95 % CI 0.92–1.23; p = 0.3848).
Analyses of time to death were therefore adjusted for cal-
endar year for treatment start.
The median treatment duration for first-line or mono-
therapy was 148 (IQR 55–299) days for sorafenib and 138
(IQR 47–296) days for sunitinib. Kaplan–Meier curves of
treatment duration and time to death, respectively, are
shown in Fig. 1. In the Poisson regression model, no
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difference was found in treatment duration between the two
groups (HR 1.00; 95 % CI 0.80–1.24; p = 0.9696).
Regarding the risk for death, no statistically significant
difference was observed for sorafenib versus sunitinib; the
HR in the unadjusted model was 1.04 (95 % CI 0.76–1.43;
p = 0.7886), and 1.30 (95 % CI 0.91–1.85; p = 0.1468) in
the model adjusted for calendar year for treatment start.
The results also showed that the later the patients were
initiated on treatment, the lower was the risk of death (HR
for calendar year for treatment start 0.71; 95 % CI
0.57–0.90; p = 0.0046).
Sequential therapy
The sequence sorafenib–sunitinib was observed among 43
patients and sunitinib–sorafenib among 54 patients. No sta-
tistically significant differences in demographics or baseline
characteristics were observed between the two groups,
except for calendar year for treatment start (Table 2).
According to hazard functions h1–h2, the calendar year
for treatment start of first-line treatment was a statistically
significant predictor for treatment stop (h2; HR 1.70; 95 %
CI 1.36–2.12; p \ 0.001), but not for the combined end-
point treatment stop or death (h1; HR 1.08; 95 % CI
0.93–1.27; p = 0.3216). Extended results from h1 to h2 are
available in the online Supplementary Material.
The median duration until treatment stop for sorafenib–
sunitinib was 252 (IQR 99–478) days, and 234 (IQR
91–413) days for sunitinib–sorafenib (n.s.), when disre-
garding the time between first- and second-line treatments.
The survival curves are shown in Fig. 2, together with the
2-year probabilities to continue treatment. No statistically
significant difference was detected in the risk to stop
treatment between the groups (h3; HR 1.47; 95 % CI
0.71–3.02) (see Table C, Supplementary Material for
extended results). The results showed that a longer duration
of first-line treatment with sunitinib was associated with an
increased risk to stop second-line treatment with sorafenib
(HR 2.86; 95 % CI 1.35–6.02; please, see Table C in the
Supplementary Material for more details). The opposite
was suggested for the time on first-line sorafenib, but this
association was not statistically significant (HR 0.72; 95 %
CI 0.34–1.52). The influence of the duration of first-line
sorafenib was therefore compared to the duration of first-
line sunitinib with a separate statistical test, described
further in the Supplementary Material. The results con-
firmed that there was a difference in how the duration of
first-line treatment with sorafenib versus with sunitinib
influenced the risk to stop second-line treatment
(p = 0.0096).
The median time until death was estimated to 398
(121–1,085) days for sorafenib–sunitinib and to 347
(102–741) days for sunitinib–sorafenib (n.s.), disregarding
the time between first- and second-line treatments. Figure 2
shows the survival curves together with the 2-year proba-
bilities to survive. The hazard function h4 is presented in
Table D, Supplementary Material. The risk for death was
not found to differ statistically between the treatment
groups, but there was a tendency toward a higher risk in the
sunitinib–sorafenib group compared to the sorafenib–sun-
itinib group (h4; HR 2.01; 95 % CI 0.86–4.68) (please, see
Table D, Supplementary Material for extended results).
The results were suggestive of a reduced risk of death with
a longer duration on first-line sorafenib (HR 0.55; 95 % CI
Table 1 Hazard functions for
analyzing the duration of
treatment and time to death
without the assumption of
patients surviving first-line
treatment
CDR cause of death register,
SPDR Swedish prescribed drug
register
a Other treatments for first-line
sorafenib and the sequence
sunitinib–sorafenib are sunitinib
or interferon alpha. Other
treatments for first-line sunitinib
and the sequence sorafenib–
sunitinib are sorafenib or
interferon alpha
Hazard
function
h1 h2 h3 h4
Type of
event
Death or treatment stop Treatment stop Treatment stop Death
Period First-line or
monotherapy
First-line or
monotherapy
Second-line therapy Second-line
therapy and
the time
beyond
Start First purchase of first-
line sorafenib or
sunitinib
First purchase of first-
line sorafenib or
sunitinib
First purchase of
second-line sorafenib
or sunitinib
First purchase
of second-
line
sorafenib or
sunitinib
End End of medication
supply, purchase of
other treatmenta, or
death, whichever
occurred first
End of medication
supply or purchase
of other treatmenta,
whichever occurred
first
End of medication
supply, purchase of
other treatmenta or
death, whichever
occurred first
Death
Censoring End of data from SPDR End of data from
SPDR or death
End of data from SPDR End of data
from CDR
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Table 2 Demographics and baseline characteristics of the patient population
Sorafenib
(n = 123)
Sunitinib
(n = 261)
p value Sorafenib–sunitinib
(n = 43)
Sunitinib–sorafenib
(n = 54)
p value
Age at diagnosis (years) 0.5872 0.1319
Mean (SD) 62.8 (10.7) 62.4 (8.7) 61.1 (8.6) 62.9 (9.3)
Median (range) 63.9 (2.0–85.2) 63.8 (22.2–81.8) 60.7 (39.8–79.3) 63.9 (22.2–76.8)
Age at medication start (years) 0.5396 0.3698
Mean (SD) 65.6 (10.3) 65.2 (8.6) 63.7 (9.0) 64.6 (9.8)
Median (range) 66.1 (19.6–88.1) 65.1 (22.4–83.6) 62.9 (45.9–84.2) 65.3 (22.4–77.9)
Sex, n (%) 0.7538 0.5066
Men 88 (71.5) 181 (69.3) 30 (69.8) 42 (77.8)
Women 35 (28.5) 80 (30.7) 13 (30.2) 12 (22.2)
Location of tumor, n (%) 0.3579 1.000
ICD-7 180.0 Kidney parenchyma 93 (75.6) 184 (70.5) 33 (76.7) 42 (77.8)
ICD-7 180.9 Kidney, NOS 30 (24.4) 77 (29.5) 10 (23.3) 12 (22.2)
Side, n (%) 0.6861 0.3242
Right 47 (44.8) 119 (47.8) 17 (44.7) 31 (57.4)
Left 58 (55.2) 130 (52.2) 21 (55.3) 23 (42.6)
T stage of primary tumor, n (%) 0.3878 0.3004
T1 16 (19.0) 31 (16.1) 4 (13.8) 9 (19.1)
T2 20 (23.8) 42 (22.3) 5 (17.2) 12 (25.5)
T3 40 (47.6) 90 (46.6) 18 (62.1) 24 (51.1)
T4 5 (6.0) 18 (9.3) 1 (3.4) 1 (2.1)
Tx 3 (3.6) 11 (5.7) 1 (3.4) 1 (2.1)
Missing 39 68 14 7
N stage (metastasis in lymph nodes),
n (%)
0.8016 0.5148
N0 33 (39.8) 69 (40.6) 10 (34.5) 19 (47.5)
N1 8 (9.6) 16 (9.4) 4 (13.8) 3 (7.5)
N2 16 (19.3) 37 (21.8) 6 (20.7) 8 (20.0)
Nx 26 (31.3) 48 (28.2) 9 (31.0) 10 (25.0)
Missing 40 91 14 14
Distant metastases, n (%) 0.3181 1.000
M0 23 (27.7) 57 (34.3) 9 (31.0) 12 (30.8)
M1 46 (55.4) 80 (48.2) 14 (48.3) 20 (51.3)
Mx 14 (16.9) 29 (17.5) 6 (20.7) 7 (17.9)
Missing 40 95 14 15
Time from RCC diagnosis to
treatment start (years)
0.5455 0.1589
Mean (SD) 2.8 (4.2) 2.8 (4.1) 2.7 (3.5) 1.7 (2.6)
Median (range) 1.0 (0.0–21.8) 0.9 (0.0–25.4) 1.3 (0.0–13.3) 0.6 (0.1–10.9)
Calendar year for treatment start,
n (%)
\0.001 \0.001
2006 27 (22.0) 4 (1.5) 14 (32.6) 1 (1.9)
2007 68 (55.3) 92 (35.2) 18 (41.9) 22 (40.7)
2008 18 (14.6) 116 (44.4) 9 (20.9) 26 (48.1)
2009 10 (8.1) 49 (18.8) 2 (4.7) 5 (9.3)
p values for comparisons of demographics and baseline characteristics between treatment groups were calculated with Mann–Whitney U test for
continuous variables, Fisher’s exact test for dichotomous variables, and Mantel–Haenszel chi-square test for ordered categorical variables
Med Oncol (2013) 30:331 Page 5 of 8
123
0.21–1.43) and an increased risk with a longer duration on
first-line sunitinib (HR 2.22; 95 % CI 0.97–5.09), although
the associations were not statistically significant. The
influence of the duration of first-line sorafenib was there-
fore compared to the duration of first-line sunitinib, with a
corresponding statistical test as described above and further
described in the Supplementary Material. The results
confirmed a difference in how the duration of first-line
treatment with sorafenib versus sunitinib influenced the
risk of death (p = 0.0278).
Discussion
No differences were detected between sorafenib and suni-
tinib regarding the duration of treatment or time to death
when used as first-line or monotherapy or as sequential
therapy. However, additional analyses showed that there
was a difference between the two treatment sequences in
how the duration of first-line treatment influenced the
duration of second-line treatment and time to death, in
favor of starting with sorafenib. There was also a trend in
favor of the sorafenib–sunitinib sequence over sunitinib–
sorafenib as time passed from treatment initiation. This was
suggested by both the survival curves and the 2-year
probabilities to continue treatment and to survive, respec-
tively, although the 2-year probabilities were based on few
observations. These findings could suggest that the out-
comes for the most severely ill patients were the same
regardless of treatment sequence, while a difference began
to emerge among patients who survived beyond the first
few months of treatment.
The results from this study are in line with several
previous retrospective studies that have observed a benefit
of the sequence sorafenib–sunitinib over sunitinib–
sorafenib [7, 12, 15, 16]. None of the prior studies resulted
in findings in favor of the sunitinib–sorafenib sequence [7,
11–17]. Sunitinib has been suggested to cause more severe
adverse events compared to sorafenib [21], which could
lead to a reduced vitality among patients and contribute to
a shorter duration of second-line treatment. Also, sunitinib
Fig. 1 Kaplan–Meier curves of treatment duration (a) and time to
death (b) with first-line or monotherapy on sorafenib and sunitinib.
According to log-rank tests, p = 0.995 for treatment duration (a) and
p = 0.767 for time to death (b)
a
b
Fig. 2 Probability to continue treatment (a) and to survive (b) with
sequential therapy on sorafenib followed by sunitinib and sunitinib
followed by sorafenib. The hazard functions illustrated in the figure
concerns initiation of first-line treatment during year 2008. The time
between the two treatments is not included. The green lines mark the
2-year probabilities to continue treatment (a) and to survive (b)
Page 6 of 8 Med Oncol (2013) 30:331
123
inhibits a wider range of tyrosine kinases compared to
sorafenib and has a higher affinity to its targets [11, 22].
The lower affinity of sorafenib may therefore permit later
salvage with sunitinib that overcomes the resistance. Fur-
ther studies are needed to increase the understanding of
these processes.
Sorafenib and sunitinib were made available to Swedish
patients at approximately the same time, but the pattern of
use showed that sorafenib was more frequently used in the
early years, while sunitinib was used more commonly
toward the end of the study period. The more severely ill
patients tend to be treated early when new treatments are
introduced, which is also supported by the higher risk of
death observed among those who initiated treatment in the
beginning of the study period. Also, the general increase in
the use of ultrasound, computed tomography (CT) scans,
and magnetic resonance imaging (MRI) over time may have
led to an unintentional discovery of smaller tumors and an
earlier diagnosis [9]. This could suggest that the less seri-
ously ill patients were more commonly treated at the end of
the study period. In this study, time from RCC diagnosis to
initiation of first-line or monotherapy was the same in both
treatment groups (2.8 years). Thus, in this regard, patients
starting with sorafenib did not appear to have been unduly
favored by factors relating to the timing of use.
Strengths and limitations
To our knowledge, this is the first study investigating the
outcomes of sequential treatment in cancer where no
assumption was made of patients surviving first-line
treatment, thereby avoiding immortal time bias. Also, this
study was based on data from Swedish national health data
registers covering all Swedish citizens. All patients who
purchased sorafenib and/or sunitinib in a Swedish phar-
macy with a diagnosis of RCC were captured. However,
patients who were solely provided their drugs via partici-
pation in early access programs for RCC treatments or only
received their drugs from the hospital during hospital
admissions are not included in this study.
The duration from RCC diagnosis to start of TKI
treatment varied between 0 and 25 years, which could
indicate a heterogeneous study population. While the
treatment groups were similar according to the measured
variables, except for calendar year for treatment start, it
cannot be excluded that the groups differed with respect to
unmeasured variables. A limitation is, for example, that the
data in the SCR are not updated in case of cancer progress,
but derived from the first time of RCC diagnosis. Infor-
mation on some factors that may influence prognosis, such
as metastatic sites, performance status, or concomitant
diseases, was not available. Reason for treatment discon-
tinuation was also unavailable.
Another limitation is that actual dosage regimens were
unknown. Patients were assumed to be treated according to
general dose recommendations. Dosages tend to vary
between patients and over time within the same patient due
to adverse effects, especially toward the end of treatment.
As dosages are generally lower at the end of treatment, the
actual duration of treatment may have been longer than
reported in this study. Also, the time between first- and
second-line treatments was not included. Collectively,
these factors could have contributed to the somewhat
shorter treatment duration observed in this study compared
to previous studies.
The data in this study suggest that the median survival
time is less efficient in detecting differences between
treatments in diseases with a short survival probability, as in
the case of RCC. A more relevant approach would perhaps
be to study survival probability at a later time point when
the most critical period after treatment initiation has passed.
Conclusion
No difference was detected between sorafenib and suniti-
nib in the duration of treatment or time to death when used
as first-line or monotherapy. However, the impact of the
duration of first-line treatment differed between the two
sequences, and results indicated that sorafenib as first-line
treatment is a favorable choice.
Acknowledgments The authors would like to thank Nils-Gunnar
Pehrsson and Aldina Pivodic at Statistiska Konsultgruppen in Goth-
enburg for support in carrying out parts of the statistical analyses.
Conflict of interest This study was partly sponsored by Bayer
HealthCare.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Socialstyrelsen [National Board of Health and Welfare]. Cancer i
siffror 2009 [Cancer in numbers 2009]. ISBN: 978-91-89446-36-
6. Stockholm, Sweden: 2011.
2. Campbell SC, Flanigan RC, Clark JI. Nephrectomy in metastatic
renal cell carcinoma. Curr Treat Options Oncol. 2003;4:363–72.
3. Escudier B, et al. Sorafenib in advanced clear-cell renal-cell
carcinoma. N Engl J Med. 2007;356:125–34.
4. Escudier B, et al. Sorafenib for treatment of renal cell carcinoma:
final efficacy and safety results of the phase III treatment
approaches in renal cancer global evaluation trial. J Clin Oncol.
2009;27:3312–8.
5. Motzer RJ, et al. Overall survival and updated results for suni-
tinib compared with interferon alfa in patients with metastatic
renal cell carcinoma. J Clin Oncol. 2009;27:3584–90.
Med Oncol (2013) 30:331 Page 7 of 8
123
6. Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 2007;356:115–24.
7. Sablin MP, et al. Sequential sorafenib and sunitinib for renal cell
carcinoma. J Urol. 2009;182:29–34.
8. Zimmermann K, et al. Sunitinib treatment for patients with
advanced clear-cell renal-cell carcinoma after progression on
sorafenib. Oncology. 2009;76:350–4.
9. Nationella arbetsgruppen fo¨r njurcancer [National working group
for renal cancer]. Nationellt va˚rdprogram—Njurcancer [National
care program—Renal cancer]. ISBN: 978-91-85947-19-5.
Stockholm, Sweden; 2010.
10. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B,
Sternberg CN. Sequential use of targeted agents in the treatment
of renal cell carcinoma. Crit Rev Oncol Hematol. 2011;77:48–62.
11. Buchler T, et al. Sunitinib followed by sorafenib or vice versa for
metastatic renal cell carcinoma–data from the Czech registry.
Ann Oncol. 2012;23:395–401.
12. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C.
Sequential therapy with sorafenib and sunitinib in renal cell
carcinoma. Cancer. 2009;115:61–7.
13. Filson CP, Redman BG, Dunn RL, Miller DC. Initial patterns of
care with oral targeted therapies for patients with renal cell car-
cinoma. Urology. 2011;77:825–30.
14. Herrmann E, et al. Sequential therapies with sorafenib and sun-
itinib in advanced or metastatic renal cell carcinoma. World J
Urol. 2011;29:361–6.
15. Porta C, et al. Sequential use of sorafenib and sunitinib in
advanced renal-cell carcinoma (RCC): an Italian multicentre
retrospective analysis of 189 patient cases. BJU Int.
2011;108:E250–7.
16. Calvani N, et al. Sequential use of sorafenib and sunitinib in
advanced renal cell carcinoma: does the order of sequencing
matter? Med Oncol. 2012;29:1908–13.
17. Buchler T, et al. Objective response and time to progression on
sequential treatment with sunitinib and sorafenib in metastatic
renal cell carcinoma. Med Oncol. 2012;29(5):3321–4.
18. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J
Epidemiol. 2008;167:492–9.
19. La¨kemedelsindustrifo¨reningens Service AB (LIF). Farmaceutiska
Specialiteter i Sverige (FASS) [Swedish medicines information
portal].
20. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA.
Lifetime risk of hip fractures is underestimated. Osteoporos Int.
1998;8:599–603.
21. Bhojani N, et al. Toxicities associated with the administration of
sorafenib, sunitinib, and temsirolimus and their management in
patients with metastatic renal cell carcinoma. Eur Urol.
2008;53:917–30.
22. Karaman MW, et al. A quantitative analysis of kinase inhibitor
selectivity. Nat Biotechnol. 2008;26:127–32.
Page 8 of 8 Med Oncol (2013) 30:331
123
